» Articles » PMID: 31664511

The Effect of Mirabegron on Bladder Blood Flow in a Rat Model of Bladder Outlet Obstruction

Overview
Journal World J Urol
Specialty Urology
Date 2019 Oct 31
PMID 31664511
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the effects of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction (BOO).

Methods: Adult female Sprague-Dawley rats were divided into three groups based on whether they underwent a sham operation (sham group) or an operation to establish partial BOO (BOO and BOO + mirabegron groups). The BOO + mirabegron group was treated with mirabegron (0.3 mg/kg/h, subcutaneously) for 14 days. Subsequently, we performed continuous cystometry, bladder blood flow measurements with a 2D laser blood flow imager, hematoxylin-eosin staining of the bladder tissue, and malondialdehyde (MDA) measurements in the bladder tissue.

Results: Cystometry revealed significantly higher peak pressure, more residual urine volume, and lower voiding efficiency in the BOO and BOO + mirabegron groups than in the sham group. The BOO + mirabegron group had significantly fewer non-voiding contractions (NVCs) than the BOO group, while the latter had more frequent NVCs than the sham group. The BOO and BOO + mirabegron groups had significantly decreased bladder blood flow than the sham group, whereas the BOO + mirabegron group showed significantly increased bladder blood flow than the BOO group. The bladder tissue in the BOO group contained more hypertrophic detrusor muscle compared to the sham group, while mirabegron treatment suppressed detrusor hypertrophy. The MDA levels were significantly higher in the BOO group than in the BOO + mirabegron and sham groups.

Conclusion: Mirabegron treatment significantly improved BOO-induced bladder dysfunction through the amelioration of bladder blood flow.

Citing Articles

Hypoxia impairs urothelial barrier function by inhibiting the expression of tight junction proteins in SV-HUC-1 cells.

Luo H, Zhou H, Chen Y, Sun X, Li Y, Li G J Cell Mol Med. 2024; 28(14):e18545.

PMID: 39031471 PMC: 11258885. DOI: 10.1111/jcmm.18545.


Molecular Regulation of Concomitant Lower Urinary Tract Symptoms and Erectile Dysfunction in Pelvic Ischemia.

Tarcan T, Choi H, Azadzoi K Int J Mol Sci. 2022; 23(24).

PMID: 36555629 PMC: 9782153. DOI: 10.3390/ijms232415988.


Multi-Omics Characterization of Circular RNA-Encoded Novel Proteins Associated With Bladder Outlet Obstruction.

Zhu B, Kang Z, Zhu S, Zhang Y, Lai X, Zhou L Front Cell Dev Biol. 2022; 9:772534.

PMID: 35071227 PMC: 8777291. DOI: 10.3389/fcell.2021.772534.


The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and....

Sakalis V, Gkotsi A, Charpidou D, Tsafrakidis P, Apostolidis A Cent European J Urol. 2021; 74(3):388-421.

PMID: 34729231 PMC: 8552938. DOI: 10.5173/ceju.2021.132.R1.

References
1.
Levin R, LEVIN S, Zhao Y, Buttyan R . Cellular and molecular aspects of bladder hypertrophy. Eur Urol. 1997; 32 Suppl 1:15-21. View

2.
Pontari M, Ruggieri M . Sex differences and role of nitric oxide in blood flow of canine urinary bladder. Am J Physiol. 1999; 276(2):R407-13. DOI: 10.1152/ajpregu.1999.276.2.R407. View